AACR:单纯雌激素替代治疗也增加乳腺癌风险

2012-04-10 卢秀玲 爱唯医学网

       根据美国护士健康研究的最新数据,长期接受单纯雌激素治疗,会增加绝经后女性发生乳腺癌的风险。布里格姆妇女医院的Wendy Chen博士在美国癌症研究学会(AACR)年会上报告的这一发现提示,不可以将不含孕激素的激素治疗看做孕激素+雌激素疗法的无风险替代选择。        &

       根据美国护士健康研究的最新数据,长期接受单纯雌激素治疗,会增加绝经后女性发生乳腺癌的风险。布里格姆妇女医院的Wendy Chen博士在美国癌症研究学会(AACR)年会上报告的这一发现提示,不可以将不含孕激素的激素治疗看做孕激素+雌激素疗法的无风险替代选择。

          为了评估与长期接受雌孕激素联合治疗和单纯雌激素治疗相关的乳腺癌风险,研究者分析了护士健康研究的28年数据。在1976年时年龄为30~55岁的121,700名受试者中,接受了10.0~14.9年和15.0~19.9年单纯雌激素治疗的女性罹患乳腺癌的风险,分别比未接受激素治疗的女性增加22%和43%。

          “我们的数据还证实了既往报道的联合激素治疗相关的风险增加。”在本项研究中,接受雌孕激素联合治疗10~14.9年的女性,罹患乳腺癌的风险比未接受激素治疗者增加88%,而接受联合治疗达20年者的风险增加1倍以上。不仅如此,乳腺癌风险并不会随着时间延长而趋于平稳,而是持续增加,即治疗时间越长则风险越高。

          在一项独立分析中,研究者严格选取健康、活动多、子宫完整的绝经后女性,年龄50~79岁。分析结果显示,接受单纯雌激素治疗不足10年时,乳腺癌风险呈下降趋势,而当治疗时间达15~20年时,乳腺癌风险则增加。

         重要的是,虽然激素治疗组的乳腺癌发病率增加,但致死性乳腺癌风险却并未增加,不论是联合治疗还是单纯雌激素治疗。其原因尚有待探讨。不过,单纯雌激素疗法的绝对风险仍然很低。在1980~2008年期间的157万人-年随访中,共诊断5,631例侵袭性乳腺癌,并有884例死于乳腺癌。          研究者还注意到,激素治疗相关风险在雌激素受体阳性乳腺癌和体型偏瘦女性中更明显。此外,如果仅对定期接受乳腺癌筛查的女性进行分析,仍得出相似结果。

          这项研究由美国国立癌症研究所资助。Chen博士无利益冲突披露。 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061310, encodeId=2e4f20613108e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Nov 15 00:50:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692817, encodeId=d50d169281e73, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 05 08:50:00 CST 2012, time=2012-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770194, encodeId=902b1e701944f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Sep 09 05:50:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400267, encodeId=57e2140026e52, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551942, encodeId=0dfa155194206, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-11-15 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061310, encodeId=2e4f20613108e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Nov 15 00:50:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692817, encodeId=d50d169281e73, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 05 08:50:00 CST 2012, time=2012-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770194, encodeId=902b1e701944f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Sep 09 05:50:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400267, encodeId=57e2140026e52, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551942, encodeId=0dfa155194206, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061310, encodeId=2e4f20613108e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Nov 15 00:50:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692817, encodeId=d50d169281e73, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 05 08:50:00 CST 2012, time=2012-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770194, encodeId=902b1e701944f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Sep 09 05:50:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400267, encodeId=57e2140026e52, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551942, encodeId=0dfa155194206, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061310, encodeId=2e4f20613108e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Nov 15 00:50:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692817, encodeId=d50d169281e73, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 05 08:50:00 CST 2012, time=2012-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770194, encodeId=902b1e701944f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Sep 09 05:50:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400267, encodeId=57e2140026e52, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551942, encodeId=0dfa155194206, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 10518094zz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061310, encodeId=2e4f20613108e, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Nov 15 00:50:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692817, encodeId=d50d169281e73, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Tue Jun 05 08:50:00 CST 2012, time=2012-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770194, encodeId=902b1e701944f, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Sep 09 05:50:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400267, encodeId=57e2140026e52, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1877, encryptionId=e7c018e7af, topicName=ACR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19792261142, createdName=10518094zz, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551942, encodeId=0dfa155194206, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1664, encryptionId=169c166430, topicName=AACR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b2714248200, createdName=Luyuxie_14, createdTime=Thu Apr 12 14:50:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 Luyuxie_14

相关资讯

PNAS:美新药有望治愈近十种癌症

       据英国《每日邮报》3月26日报道,美国科学家日前研制出了一种能帮助人体免疫系统摧毁癌细胞的新型药物,对乳腺癌、肠癌、前列腺癌、子宫癌、脑癌、膀胱癌、肝癌等多种癌症都有疗效。此外前期研究表明,该药物还可用于治疗血癌(白血病)。研究人员表示,若能及早使用,该药物甚至可以完全治愈恶性肿瘤疾病,且副作用极小。(Proc Natl Acad Sci U

JAMA:乳腺造影联合超声波或MRI对乳腺癌高风险妇女有益

       据4月4日刊《美国医学会期刊》上的一项研究披露,在对那些乳腺癌风险增加且乳腺组织致密的妇女进行每年乳腺造影筛查之外再加上一种筛检性超声波检查或核磁共振成像(MRI)可令附带性发现乳腺癌的比率增加。(JAMA. 2012;307(13):1394-1404)        根据文章的背景资料:&l

曲妥珠单抗Emtansine治疗乳腺癌III期研究结果公布

       罗氏公司于3月30日发布其III期临床试验(EMILIA)的公告。这项试验比较了该公司的新药曲妥珠单抗Emtansine与标准疗法拉帕替尼+希罗达®(卡培他滨)治疗HER-2阳性转移性乳腺癌的疗效。        该研究纳入的患者既往曾接受赫赛汀®和ataxane(化疗)治疗。该

热点探讨:乳腺癌治疗四大决策

       2012年3月17日,第三届诺华乳腺癌高峰论坛在海南三亚召开。复旦大学附属肿瘤医院邵志敏教授、中国医学科学院肿瘤医院徐兵河教授、辽宁省肿瘤医院张斌教授、华中科技大学同济医学院附属同济医院于世英教授和解放军307医院江泽飞教授应邀担任大会主席,携手多位国内乳腺癌治疗领域专家,通过主题报告和病例研讨对乳腺癌治疗的热点问题进行了探讨。其中,来曲唑(弗

美最高法院要求重审乳腺癌基因专利案

       美国最高法院3月26日做出裁决,要求联邦巡回上诉法院重新审理涉及万基遗传科技公司的乳腺癌基因专利案。           联邦巡回上诉法院专门负责审理专利案件。该院去年7月曾裁定,万基公司可以拥有针对乳腺癌测试基因BRCA1和BRCA2的专利。

PLoS One:中国汉族乳腺癌与IL-17多态性关联分析

目前,乳腺癌病因学的研究主要集中在免疫及炎症方面。已知促炎症因子IL-17A和IL-17F能够介导炎症和癌症的发生。为了评估在乳腺癌风险中IL-17A和IL-17F基因多态性的作用,来自中国哈尔滨医科大学肿瘤预防及治疗中心的庞达教授及其课题组在中国汉族女性中开展了一个乳腺癌病例对照研究。研究发现,IL-17A中的单核苷酸多态性与乳腺癌发生风险有关。相关文章发表在3月26日的美国《公共科学图书馆·综